Efficacy and safety of newer-generation antidepressants medications in Parkinson's disease with depression - A meta-analysis of randomized controllde trials

IF 3.7 2区医学 Q1 PSYCHIATRY

Journal of psychiatric research Pub Date : 2025-02-25 DOI:10.1016/j.jpsychires.2025.02.044

Fenghua Xu , Wei Zhou , Haiyan Luo , Dongyun Su , Meng Dong , Yang Hu , Manxue Lou , Gongbo Li , Yuqing Zhang

{"title":"Efficacy and safety of newer-generation antidepressants medications in Parkinson's disease with depression - A meta-analysis of randomized controllde trials","authors":"Fenghua Xu , Wei Zhou , Haiyan Luo , Dongyun Su , Meng Dong , Yang Hu , Manxue Lou , Gongbo Li , Yuqing Zhang","doi":"10.1016/j.jpsychires.2025.02.044","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Depression is common as non-motor symptom in Parkinson's disease (PD). Evidence of antidepressants for PD with depression remain unclear. This meta-analysis examines the efficacy and tolerability of newer-generation antidepressants for PD with depression.</div></div><div><h3>Methods</h3><div>Six international electronic databases (Cochrane, PubMed, Embase, Web of Science, CINAHL, and PsycINFO) and four Chinese electronic databases (CBM, CNKI, WanFang Data, and VIP) were systematically searched up to October 31, 2023. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (all-cause discontinuations). Secondary outcomes contained improvement in motor symptoms, change score of anxiety rating scales, improvement in cognitive function, and adverse events. This study was registered with PROSPERO, number CRD42020198364.</div></div><div><h3>Result</h3><div>A total of 11 trials with 713 participants were included. Newer-generation antidepressants significantly improved depressive symptoms (standardized mean differences (SMD) = −1.12 [−1.72; −0.52]), anxiety scores (SMD = −0.60 [−1.04; −0.17]). However, there was insufficient evidence in improving motor function in PD (SMD = −1.19 [−2.74; 0.36]) and the cognitive function (SMD = 0.57 [−0.33; 1.47]). Newer-generation antidepressants were associated with increased diminished sexual desire (RR = 2.34 [1.13; 4.86]) and insomnia (RR = 0.42 [0.22; 0.82]), but similar risk of all-cause discontinuations when compared with the control group (RR = 1.25 [0.85; 1.85]).</div></div><div><h3>Conclusion</h3><div>Newer-generation antidepressants appear to be beneficial and safe in treating depression in PD.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"184 ","pages":"Pages 48-55"},"PeriodicalIF":3.7000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychiatric research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022395625001232","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Depression is common as non-motor symptom in Parkinson's disease (PD). Evidence of antidepressants for PD with depression remain unclear. This meta-analysis examines the efficacy and tolerability of newer-generation antidepressants for PD with depression.

Methods

Six international electronic databases (Cochrane, PubMed, Embase, Web of Science, CINAHL, and PsycINFO) and four Chinese electronic databases (CBM, CNKI, WanFang Data, and VIP) were systematically searched up to October 31, 2023. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (all-cause discontinuations). Secondary outcomes contained improvement in motor symptoms, change score of anxiety rating scales, improvement in cognitive function, and adverse events. This study was registered with PROSPERO, number CRD42020198364.

Result

A total of 11 trials with 713 participants were included. Newer-generation antidepressants significantly improved depressive symptoms (standardized mean differences (SMD) = −1.12 [−1.72; −0.52]), anxiety scores (SMD = −0.60 [−1.04; −0.17]). However, there was insufficient evidence in improving motor function in PD (SMD = −1.19 [−2.74; 0.36]) and the cognitive function (SMD = 0.57 [−0.33; 1.47]). Newer-generation antidepressants were associated with increased diminished sexual desire (RR = 2.34 [1.13; 4.86]) and insomnia (RR = 0.42 [0.22; 0.82]), but similar risk of all-cause discontinuations when compared with the control group (RR = 1.25 [0.85; 1.85]).

Conclusion

Newer-generation antidepressants appear to be beneficial and safe in treating depression in PD.

查看原文本刊更多论文

新一代抗抑郁药物对帕金森病合并抑郁症患者的疗效和安全性--随机对照试验荟萃分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of psychiatric research 医学-精神病学

CiteScore

7.30

自引率

2.10%

发文量

622

审稿时长

130 days

期刊介绍： Founded in 1961 to report on the latest work in psychiatry and cognate disciplines, the Journal of Psychiatric Research is dedicated to innovative and timely studies of four important areas of research: (1) clinical studies of all disciplines relating to psychiatric illness, as well as normal human behaviour, including biochemical, physiological, genetic, environmental, social, psychological and epidemiological factors; (2) basic studies pertaining to psychiatry in such fields as neuropsychopharmacology, neuroendocrinology, electrophysiology, genetics, experimental psychology and epidemiology; (3) the growing application of clinical laboratory techniques in psychiatry, including imagery and spectroscopy of the brain, molecular biology and computer sciences;